[The results of radiotherapy managements in Hodgkin's disease (author's transl)].
We reported the results of radiotherapy managements in Hodgkin's disease about 185 patients. From this study, it seems to appear possible to confirm or to note some particular facts: the real good prognosis of the forms begining in the right sus-clavicular fossa; the special staging of the long time survival patients (II Aa, type II); the small value in survival of chemotherapy done before and/or after radiotherapy in the I and II stages; in the other side, the true amelioration comming from chemotherapy in the III and IV stages; the value of irradiation by expanded fields; the particular interest of the total mode irradiation done at the beginning or during the course of the illness; the optimal dose of larger than or equal to 4 000 rads with a weekly dose of larger than or equal to 1 000 rads; the good tolerance of the radiotherapy. From this prelimary study, we hope dowing well in further with a greater number of patients.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011379:Prognosis; D011878:Radiotherapy / Q000009:adverse effects; D012189:Retrospective Studies; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D011241:Prednisone
Résultats de la radiothérapie dans la maladie de Hodgkin.